home / stock / mtcr / mtcr news

MTCR News and Press, Metacrine Inc. From 10/21/21

Stock Information
Company Name: Metacrine Inc.
Stock Symbol: MTCR
Market: NASDAQ
Website: metacrine.com
Menu
MTCR MTCR Quote MTCR Short MTCR News MTCR Articles MTCR Message Board
Get MTCR Alerts

News, Short Squeeze, Breakout and More Instantly...
MTCR - Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the effi...
MTCR - IVAC, ERYP, CMTL and SABR among after hours movers

Gainers: IVAC +7.3%. ERYP +7.3%. FATE +5.3%. CHX +4.8%. XP +3.9%. Losers: CMTL -12.4%. SABR -5.4%. MTCR -2.6%. ZY -2.1%. HAIN -1.9%. For further details see: IVAC, ERYP, CMTL and SABR among after hours movers

MTCR - NAKD, CAN and RWLK among mid-day movers

Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +71%. Aehr Test (NASDAQ:AEHR) +36%. Unique Fabricating (NYSE:UFAB) +32%. Meredith (NYSE:MDP) +26%. Paltalk (NASDAQ:PALT) +24%. Marin Software (NASDAQ:MRIN) +22%. ReWalk Robotics (NASDAQ:RWLK) +20%. Metacrine (NASDAQ:MTCR) +17%. Naked Brand Group (NASDAQ:...

MTCR - Leap Therapeutics, aTyr Pharma lead healthcare gainers; Silverback Therapeutics, Aerie Pharmaceuticals among major losers

Gainers: Leap Therapeutics (NASDAQ:LPTX) +23%, aTyr Pharma (NASDAQ:LIFE) +16%, Metacrine (NASDAQ:MTCR) +9%, MedAvail Holdings (NASDAQ:MDVL) +7%. Losers: Silverback Therapeutics (NASDAQ:SBTX) -28%, Aerie Pharmaceuticals (NASDAQ:AERI) -27%,...
MTCR - LAUR, LPTX, AERI and TWKS among after hours movers

Gainers: TMC +8.2%. LAUR +7.6%. LPTX +6.7%. TTD +5.9%. GREE +4.4%. Losers: AERI -15.3%. TWKS -4.8%. TVTX -4.3%. PEGA -3.9%. MTCR -3.5% For further details see: LAUR, LPTX, AERI and TWKS among after hours movers

MTCR - Catalyst watch for next week: Apple, Zoom Video, Palo Alto Networks in the spotlight; OPEC update

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

MTCR - Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

Exceeded enrollment target of 180 total patients Interim data from the first 60 patients expected early in the fourth quarter of 2021 Topline MET642 trial results from all patients are anticipated in the first half of 2022 SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSW...
MTCR - Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies f...

MTCR - Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive o...

MTCR - Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021 Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes on track to be reported in the fourth...
Previous 10 Next 10